PL365292A1 - Zastosowanie długiej pentraksyny PTX3 do leczeniaschorzeń spowodowanych zmienioną aktywacją czynnika wzrostu FGF-2 - Google Patents

Zastosowanie długiej pentraksyny PTX3 do leczeniaschorzeń spowodowanych zmienioną aktywacją czynnika wzrostu FGF-2

Info

Publication number: PL365292A1
Authority: PL; Poland
Prior art keywords: growth factor; treatment; factor fgf; diseases caused; long pentraxin
Prior art date: 2000-11-08

Application number

PL01365292A

Other languages

English (en)

Other versions

PL205925B1 (pl

Inventor

Alberto Mantovani

Barbara Bottazzi

Marco Presta

Marco Rusnati

Original Assignee

Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-08

Filing date

2001-11-08

Publication date

2004-12-27

2001-11-08 Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

2004-12-27 Publication of PL365292A1 publication Critical patent/PL365292A1/pl

2010-06-30 Publication of PL205925B1 publication Critical patent/PL205925B1/pl

Links

239000003102 growth factor Substances 0.000 title abstract 3
230000004913 activation Effects 0.000 title abstract 2
201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
101150019331 FGF2 gene Proteins 0.000 title 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 2
101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 abstract 2
BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 abstract 2
102100027351 Pentraxin-related protein PTX3 Human genes 0.000 abstract 2
230000004071 biological effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Rheumatology (AREA)
Marine Sciences & Fisheries (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Oncology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)

PL365292A 2000-11-08 2001-11-08 Zastosowanie długiej pentraksyny PTX3 lub cDNA kodującego długą pentraksynę PTX3 PL205925B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2000RM000578A IT1317930B1 (it)	2000-11-08	2000-11-08	Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
PCT/IT2001/000563 WO2002038169A1 (en)	2000-11-08	2001-11-08	Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2

Publications (2)

Publication Number	Publication Date
PL365292A1 true PL365292A1 (pl)	2004-12-27
PL205925B1 PL205925B1 (pl)	2010-06-30

Family

ID=11454983

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL365292A PL205925B1 (pl)	2000-11-08	2001-11-08	Zastosowanie długiej pentraksyny PTX3 lub cDNA kodującego długą pentraksynę PTX3

Country Status (21)

Country	Link
US (1)	US7858577B2 (pl)
EP (1)	EP1331940B1 (pl)
JP (1)	JP4167061B2 (pl)
KR (1)	KR100822357B1 (pl)
CN (1)	CN1304047C (pl)
AT (1)	ATE322906T1 (pl)
AU (2)	AU2002222513B8 (pl)
BR (1)	BR0115190A (pl)
CA (1)	CA2428176C (pl)
CY (1)	CY1106092T1 (pl)
CZ (1)	CZ299673B6 (pl)
DE (1)	DE60118769T2 (pl)
DK (1)	DK1331940T3 (pl)
ES (1)	ES2261515T3 (pl)
HU (1)	HU229100B1 (pl)
IT (1)	IT1317930B1 (pl)
MX (1)	MXPA03004005A (pl)
PL (1)	PL205925B1 (pl)
PT (1)	PT1331940E (pl)
SK (1)	SK287791B6 (pl)
WO (1)	WO2002038169A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1298487B1 (it) *	1997-12-19	2000-01-10	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20020109A1 (it) *	2002-02-28	2003-08-28	Sigma Tau Ind Farmaceuti	Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM20020191A1 (it) *	2002-04-08	2003-10-08	Sigma Tau Ind Farmaceuti	Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ITRM20030596A1 (it) *	2003-12-23	2005-06-24	Sigma Tau Ind Farmaceuti	Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
WO2005080981A1 (ja) *	2004-02-25	2005-09-01	Perseus Proteomics Inc.	血管障害の程度の判定方法
ITRM20040489A1 (it)	2004-10-08	2005-01-08	Sigma Tau Ind Farmaceuti	Pentraxina lunga ptx3 deglicosilata o desialidata.
MX2008009289A (es) *	2006-01-24	2008-10-17	Tecnogen Spa	Peptidos de enlace al factor de crecimiento de fibroblasto 2 y usos de los mismos.
EP1832295A1 (en) *	2006-03-10	2007-09-12	Tecnogen S.P.A.	Use of PTX3 for the treatment of viral diseases
JP5441685B2 (ja)	2006-05-02	2014-03-12	シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ	チモシンα１の、単独またはＰＴＸ３またはガンシクロビルとの組合せにおける、サイトメガロウイルス感染の処置のための使用
WO2013191280A1 (ja) *	2012-06-22	2013-12-27	国立大学法人東京大学	全身性炎症反応症候群の治療又は予防剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0571442A4 (en) *	1991-01-14	1995-05-03	Univ New York	CYTOKIN INDUCIBLE PROTEIN TSG-14, ITS ENCODING DNA AND THEIR USE.
IT1298487B1 (it) *	1997-12-19	2000-01-10	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,

2000
- 2000-11-08 IT IT2000RM000578A patent/IT1317930B1/it active
2001
- 2001-11-08 DE DE60118769T patent/DE60118769T2/de not_active Expired - Lifetime
- 2001-11-08 KR KR1020037006278A patent/KR100822357B1/ko not_active Expired - Fee Related
- 2001-11-08 PT PT01993471T patent/PT1331940E/pt unknown
- 2001-11-08 US US10/416,225 patent/US7858577B2/en not_active Expired - Fee Related
- 2001-11-08 EP EP01993471A patent/EP1331940B1/en not_active Expired - Lifetime
- 2001-11-08 CA CA2428176A patent/CA2428176C/en not_active Expired - Fee Related
- 2001-11-08 ES ES01993471T patent/ES2261515T3/es not_active Expired - Lifetime
- 2001-11-08 SK SK562-2003A patent/SK287791B6/sk not_active IP Right Cessation
- 2001-11-08 CN CNB018185630A patent/CN1304047C/zh not_active Expired - Fee Related
- 2001-11-08 JP JP2002540751A patent/JP4167061B2/ja not_active Expired - Fee Related
- 2001-11-08 WO PCT/IT2001/000563 patent/WO2002038169A1/en not_active Ceased
- 2001-11-08 CZ CZ20031179A patent/CZ299673B6/cs not_active IP Right Cessation
- 2001-11-08 DK DK01993471T patent/DK1331940T3/da active
- 2001-11-08 BR BR0115190-8A patent/BR0115190A/pt active Search and Examination
- 2001-11-08 HU HU0400541A patent/HU229100B1/hu not_active IP Right Cessation
- 2001-11-08 AT AT01993471T patent/ATE322906T1/de active
- 2001-11-08 PL PL365292A patent/PL205925B1/pl unknown
- 2001-11-08 AU AU2002222513A patent/AU2002222513B8/en not_active Ceased
- 2001-11-08 MX MXPA03004005A patent/MXPA03004005A/es active IP Right Grant
- 2001-11-08 AU AU2251302A patent/AU2251302A/xx active Pending
2006
- 2006-06-05 CY CY20061100719T patent/CY1106092T1/el unknown

Also Published As

Publication number	Publication date
AU2002222513B8 (en)	2006-11-23
AU2002222513B2 (en)	2006-10-26
KR20030061396A (ko)	2003-07-18
HUP0400541A3 (en)	2006-01-30
JP2004513151A (ja)	2004-04-30
CY1106092T1 (el)	2011-06-08
CZ299673B6 (cs)	2008-10-15
HK1061209A1 (en)	2004-09-10
PT1331940E (pt)	2006-07-31
AU2251302A (en)	2002-05-21
DE60118769D1 (de)	2006-05-24
US20040023879A1 (en)	2004-02-05
ITRM20000578A1 (it)	2002-05-08
CA2428176C (en)	2013-02-05
KR100822357B1 (ko)	2008-04-16
DE60118769T2 (de)	2007-01-04
ES2261515T3 (es)	2006-11-16
US7858577B2 (en)	2010-12-28
SK287791B6 (sk)	2011-10-04
CA2428176A1 (en)	2002-05-16
HU229100B1 (en)	2013-07-29
PL205925B1 (pl)	2010-06-30
BR0115190A (pt)	2004-02-03
WO2002038169A1 (en)	2002-05-16
DK1331940T3 (da)	2006-08-14
EP1331940A1 (en)	2003-08-06
EP1331940B1 (en)	2006-04-12
MXPA03004005A (es)	2004-05-05
CN1304047C (zh)	2007-03-14
ATE322906T1 (de)	2006-04-15
HUP0400541A2 (hu)	2004-05-28
JP4167061B2 (ja)	2008-10-15
IT1317930B1 (it)	2003-07-15
CN1473050A (zh)	2004-02-04
SK5622003A3 (en)	2003-10-07
CZ20031179A3 (cs)	2003-11-12

Publication	Publication Date	Title
AU672018B2 (en)	1996-09-19	Looped, hairpin ribozyme
DE60023043D1 (de)	2006-02-16	(S,S)-Reboxetin zur Behandlung von Inkontinenz
NZ504026A (en)	2002-12-20	Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
KR920019342A (ko)	1992-11-19	골질환 치료제
HK1045816A1 (zh)	2002-12-13	角质细胞生长因子-2制剂
BRPI0414215A (pt)	2006-11-07	tienopirazóis
AU2251302A (en)	2002-05-21	Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
EE200300504A (et)	2003-12-15	3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
SE0102147D0 (sv)	2001-06-18	New methods
ZA991749B (en)	1999-09-16	Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy.
DE60113304D1 (de)	2005-10-13	Verwendung von langem pentraxin ptx3 zur herstellung eines arzneimittels zur verhütung und heilung von autoimmunkrankheiten
AU6309398A (en)	1998-10-12	Agent for preventing and/or treating cachexia
MXPA03011186A (es)	2004-02-26	Uso de pentraxina ptx3 de cadena larga para tratamiento contra enfermedades tumorales mediadas por fgf-8.
WO2001089558A3 (en)	2002-09-12	Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
NO995692D0 (no)	1999-11-19	Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
EE200300495A (et)	2003-12-15	3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
AP2009004857A0 (en)	2009-06-30	Oxidized proteins, their biological activity, and therapeutic and diagnostic measures,which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
PT869785E (pt)	2002-12-31	4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
EE200300506A (et)	2004-02-16	3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
DE3769497D1 (de)	1991-05-29	Mittel zur bekaempfung von phytopathogenen mikroben.
DE59805246D1 (de)	2002-09-26	Tissue-faktor zur beeinflussung von gefässbildung
DE60122781D1 (de)	2006-10-12	Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
BR0303384A (pt)	2004-03-30	Citalopram e seus usos no tratamento de pressão sanguìnea elevada
SE9902674D0 (sv)	1999-07-12	New composition
UA32315A (uk)	2000-12-15	Спосіб накладання шкірного шва